Maxim Group Analysts Give Vistagen Therapeutics (NASDAQ:VTGN) a $4.00 Price Target

Vistagen Therapeutics (NASDAQ:VTGN) has been assigned a $4.00 price target by analysts at Maxim Group in a note issued to investors on Tuesday, TipRanks reports. The firm presently has a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 277.36% from the stock’s current price.

VTGN has been the topic of a number of other reports. William Blair restated a “buy” rating on shares of Vistagen Therapeutics in a research report on Wednesday. ValuEngine upgraded shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Chardan Capital restated a “neutral” rating on shares of Vistagen Therapeutics in a research report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $3.57.

Shares of VTGN stock traded down $0.03 during midday trading on Tuesday, reaching $1.06. 161,237 shares of the company were exchanged, compared to its average volume of 315,173. Vistagen Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.32. The company has a market cap of $44.92 million, a P/E ratio of -1.18 and a beta of -0.30. The company’s 50 day moving average price is $0.96 and its two-hundred day moving average price is $0.84. The company has a debt-to-equity ratio of 2.44, a quick ratio of 2.65 and a current ratio of 2.65.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Friday, August 16th. The company reported ($0.15) EPS for the quarter. As a group, sell-side analysts predict that Vistagen Therapeutics will post -1.26 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after purchasing an additional 35,729 shares in the last quarter. LPL Financial LLC bought a new stake in shares of Vistagen Therapeutics in the 2nd quarter worth approximately $27,000. Wells Fargo & Company MN bought a new stake in shares of Vistagen Therapeutics in the 2nd quarter worth approximately $31,000. HighTower Advisors LLC raised its holdings in shares of Vistagen Therapeutics by 326.3% in the 2nd quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock worth $96,000 after purchasing an additional 101,308 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its holdings in shares of Vistagen Therapeutics by 37.2% in the 1st quarter. Sphera Funds Management LTD. now owns 2,022,066 shares of the company’s stock worth $2,588,000 after purchasing an additional 548,148 shares in the last quarter. Institutional investors own 7.54% of the company’s stock.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: How to execute a trade ex-dividend strategy?

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.